Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Account Payables: 2013-2025

Historic Change in Account Payables for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -$1.3 million.

  • Ocular Therapeutix's Change in Account Payables fell 528.28% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $578,000, marking a year-over-year increase of 155.75%. This contributed to the annual value of -$318,000 for FY2024, which is 154.55% down from last year.
  • Per Ocular Therapeutix's latest filing, its Change in Account Payables stood at -$1.3 million for Q3 2025, which was down 173.48% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Change in Account Payables registered a high of $1.7 million during Q2 2025, and its lowest value of -$2.4 million during Q2 2024.
  • For the 3-year period, Ocular Therapeutix's Change in Account Payables averaged around $66,455, with its median value being $247,000 (2023).
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 745.34% in 2021, then slumped by 542.43% in 2023.
  • Ocular Therapeutix's Change in Account Payables (Quarterly) stood at $366,000 in 2021, then tumbled by 406.56% to -$1.1 million in 2022, then surged by 158.47% to $656,000 in 2023, then plummeted by 82.93% to $112,000 in 2024, then slumped by 528.28% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, $1.7 million for Q2 2025, and $7,000 during Q1 2025.